| # | Aladdin ID | Assay Type | Description | Organism | Compounds | Reference | BAO Format | Source | |
|---|---|---|---|---|---|---|---|---|---|
| 1. | ALA3365787 | B | Inhibition of human recombinant GIVA cPLA2 using 400 uM Triton X-100/97 uM PAPC/1.8 uM 14C-labeled PAPC/3uM PIP2 substrate mixedmicelles at 1 uM | Homo sapiens | 9 | ALA3352663 | single protein format | Scientific Literature | |
| 2. | ALA3365788 | B | Inhibition of human recombinant GIVA cPLA2 using 400 uM Triton X-100/97 uM PAPC/1.8 uM 14C-labeled PAPC/3uM PIP2 substrate mixedmicelles | Homo sapiens | 3 | ALA3352663 | single protein format | Scientific Literature | |
| 3. | ALA3365789 | B | Inhibition of human recombinant GIVA iPLA2 using 400 uM Triton X-100/98.3 uM PAPC/1.7 uM 14C-labeled PAPC substrate mixedmicelles at 1 uM | Homo sapiens | 9 | ALA3352663 | assay format | Scientific Literature | |
| 4. | ALA3365790 | B | Inhibition of human recombinant GV sPLA2 using 400 uM Triton X-100/98.3 uM PAPC/1.7 uM 14C-labeled PAPC substrate mixedmicelles at 1 uM | Homo sapiens | 9 | ALA3352663 | assay format | Scientific Literature | |
| 5. | ALA3365791 | B | Inhibition of human recombinant GIVA cPLA2 at 1 uM in vitro vesicle assay | Homo sapiens | 9 | ALA3352663 | single protein format | Scientific Literature | |
| 6. | ALA3365792 | B | Inhibition of human recombinant GIVA cPLA2 in vitro vesicle assay | Homo sapiens | 7 | ALA3352663 | single protein format | Scientific Literature | |
| 7. | ALA3365793 | F | Inhibition of IL-1beta-induced arachidonic acid release in human SW982 cells using [3H]AA at 10 uM by liquid scintillation counting | Homo sapiens | 9 | ALA3352663 | cell-based format | Scientific Literature | |
| 8. | ALA3365794 | F | Inhibition of IL-1beta-induced arachidonic acid release in human SW982 cells using [3H]AA by liquid scintillation counting | Homo sapiens | 7 | ALA3352663 | cell-based format | Scientific Literature | |
| 9. | ALA3365795 | F | Inhibition of IL-1beta-induced oleic acid release in human SW982 cells using [3H]OA at 10 uM by liquid scintillation counting | Homo sapiens | 6 | ALA3352663 | cell-based format | Scientific Literature | |
| 10. | ALA3365797 | T | Toxicity in mouse at 1 to 60 mg/kg, ip for 1 week | Mus musculus | 1 | ALA3352663 | organism-based format | Scientific Literature | |
| 11. | ALA3365798 | F | Antiinflammatory activity in DBA/1 mouse assessed as inhibition of carrageenan-induced arthritis at 7.5 mg/kg, ip treatment started on day 21 after second carrageenan challenge measured on day 32 to 41 | Mus musculus | 1 | ALA3352663 | organism-based format | Scientific Literature | |
| 12. | ALA3365800 | F | Antiinflammatory activity in DBA/1 mouse carrageenan-induced arthritis model assessed as reduction in articular cavity at 7.5 mg/kg, ip treatment started on day 21 after second carrageenan challenge measured on day 32 | Mus musculus | 2 | ALA3352663 | organism-based format | Scientific Literature | |
| 13. | ALA3365801 | F | Antiinflammatory activity in DBA/1 mouse carrageenan-induced arthritis model assessed as reduction in peripheral tissue inflammatory cell infiltration at 7.5 mg/kg, ip treatment started on day 21 after second carrageenan challenge measured on day 32 | Mus musculus | 2 | ALA3352663 | organism-based format | Scientific Literature | |
| 14. | ALA3365802 | F | Antiinflammatory activity in DBA/1 mouse carrageenan-induced arthritis model assessed as reduction in capillary and synovial hyperplasia at 7.5 mg/kg, ip treatment started on day 21 after second carrageenan challenge measured on day 32 | Mus musculus | 2 | ALA3352663 | organism-based format | Scientific Literature | |
| 15. | ALA3365803 | F | Antiinflammatory activity in DBA/1 mouse assessed as inhibition of carrageenan-induced arthritis index at 7.5 mg/kg, ip treatment started on day 7 after second carrageenan challenge | Mus musculus | 1 | ALA3352663 | organism-based format | Scientific Literature | |
| 16. | ALA3365804 | F | Antiinflammatory activity in DBA/1 mouse assessed as inhibition of carrageenan-induced arthritis index at 30 mg/kg, ip treatment started on day 7 after second carrageenan challenge measured on day 36 to 41 | Mus musculus | 1 | ALA3352663 | organism-based format | Scientific Literature | |
| 17. | ALA3365805 | F | Reduction in PGE2 level in DBA/1 mouse plasma at 7.5 mg/kg, ip by EIA analysis relative to control | Mus musculus | 1 | ALA3352663 | organism-based format | Scientific Literature | |
| 18. | ALA3362492 | F | Reduction in PGE2 level in DBA/1 mouse plasma at 30 mg/kg, ip by EIA analysis relative to control | Mus musculus | 1 | ALA3352663 | organism-based format | Scientific Literature | |
| 19. | ALA3362493 | A | Half life in human whole blood | Homo sapiens | 1 | ALA3352663 | tissue-based format | Scientific Literature | |
| 20. | ALA3362494 | A | Half life in mouse plasma | Mus musculus | 1 | ALA3352663 | cell-free format | Scientific Literature |
The page will load shortly, Thanks for your patience!